ArticleSurgical case reports2025
A Case Report of Severe Thrombocytopenic Purpura during Neoadjuvant Pembrolizumab Administration for Triple-Negative Breast Cancer.
Article in Surgical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionImmune thrombocytopenic purpura (ITP) is one of the immune-related adverse events (irAEs) related to immune checkpoint inhibitors (ICIs). Here, we report a case of a 51-year-old woman with triple-negative breast cancer (TNBC) who experienced severe thrombocytopenic purpura during the neoadjuvant chemotherapy (NAC), including pembrolizumab. CASE PRESENTATION: A 51-year-old woman was diagnosed with Stage II B TNBC and underwent NAC using pembrolizumab + paclitaxel + carboplatin. Her blood test on cycle 4, day 15 (C4D15) showed a significant decrease in platelets to <2000/μL accompanied by overt bleeding tendency. She was hospitalized for further investigation and treatment. Her platelet count recovered after platelet concentrate transfusion and corticosteroid administration. Her bone marrow examination showed normal cellularity, and she was judged as ITP. Due to the event and good clinical response to NAC, she underwent a right partial mastectomy and axillary lymph node dissection without completion of the planned NAC. The surgical specimen showed a complete pathological response.
conclusionsThrombocytopenia is known as one of the hematologic irAEs; however, severe thrombocytopenia with a bleeding tendency is rarely reported. Sufficient explanations to patients and appropriate referral to other related departments are important for earlier detection and treatment of irAE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.